On September 3, 2025, Tenax Therapeutics, Inc. (the "Company") and Orion Corporation ("Orion") entered into an amendment (the "Amendment") to that certain License Agreement between the Company and Orion dated as of September 20, 2013, as previously amended on October 9, 2020, January 25, 2022, February 19, 2024, and October 2, 2024 (the "Agreement"). Under the Amendment, the Company's licenses from Orion have been expanded to include exclusive worldwide rights to develop, commercialize, manufacture, and have manufactured any orally-administered pharmaceutical product containing levosimendan and, in addition to the Company's existing rights to develop or commercialize subcutaneously administered products containing levosimendan, to manufacture or have manufactured such products. The Amendment also calls for Orion to supply the Company with levosimendan to the extent reasonably necessary or useful to manufacture orally-administered products containing levosimendan for purposes of developing such products, and sets forth the terms for such supply, including the price of levosimendan ordered by the Company of low triple-digit thousands in Euros per kilogram, payment terms, and active pharmaceutical ingredient specifications.